Fund IV Closes Oversubscribed at $425 Million
Frist Cressey Ventures (FCV) has officially closed its oversubscribed Fund IV at $425 million, bringing the firm’s total assets under management to nearly $1 billion. The successful close reflects overwhelming confidence from strategic partners and investors in FCV’s distinctive approach to early-stage healthcare investing. Fund IV will expand the firm’s platform capabilities, deepen its founder-support infrastructure, and continue accelerating innovation across care delivery through technology and tech-enabled services — including AI-native business models.
The milestone is particularly significant given the current investment climate, where oversubscribed healthcare funds signal not just investor appetite, but genuine belief in a firm’s long-term thesis and execution ability. FCV has clearly earned that trust.
A Decade of Proven Healthcare Investment Success
The close of Fund IV coincides with FCV’s ten-year anniversary, marking a decade of disciplined, impact-driven investing across the healthcare landscape. To date, the firm has made 44 total investments and achieved 14 successful exits — a portfolio that demonstrates both breadth and selectivity. Fund I and Fund II have each ranked in the top 5% of all venture capital funds for their respective vintages, emerging as benchmarks for performance in the healthcare VC space.
This track record positions FCV as a partner of choice for ambitious founders navigating complex healthcare markets. Robin Shah, CEO and co-founder of Thyme Care, highlighted this value: “Frist Cressey Ventures believed in Thyme Care’s model early, before the category was clearly defined, and has stayed committed as we have grown into a category-defining leader in specialty care management. The firm has been a close partner and mentor throughout that journey.”
Justin Norden, CEO and co-founder of Qualified Health, echoed that sentiment: “FCV brings a rare combination of healthcare experience and long-term strategic thinking. As we build the operating layer that enables health systems to deploy governed AI across the enterprise, their support has been grounded in a clear understanding of both the urgency and complexity of this moment in healthcare.”
Strategic Partners Driving Broader Healthcare Impact
FCV’s strategic limited partners — including The Cigna Group Ventures, MedStar Health, and OhioHealth — collectively provide healthcare services to more than 50% of the U.S. population. This expansive network isn’t merely a fundraising asset; it’s a core differentiator that gives FCV portfolio companies unparalleled access, distribution pathways, and real-world validation opportunities.
Craig Cimini, Head of The Cigna Group Ventures, noted: “Advancing a simpler, more connected healthcare experience requires a shared commitment to collaboration and continuous innovation across the industry. Our collaboration with Frist Cressey will help advance solutions that drive better health outcomes, affordability, and experiences for the people we serve.”
Bill Sheahan, Senior Vice President and Chief Innovation Officer of MedStar Health, added: “We have a greater opportunity than ever to use tech to address some of the most complex challenges in healthcare. Frist Cressey helps us identify real innovations, and advises on where we should be spending our time and capital.”
Jesse Longoria, Senior Vice President and Chief Strategy & Growth Officer of OhioHealth, reinforced the value of the partnership: “The collaboration with Frist Cressey will help us see around corners and bring innovative opportunities to our organization.”
Notably, 25% of FCV’s portfolio companies include at least one investor from among its strategic partners — a powerful indicator of alignment between the firm’s investment thesis and its LP base.
AI and Tech-Enabled Care at the Core
Fund IV maintains FCV’s sharp focus on early-stage companies that are transforming care delivery through technology. This includes companies leveraging AI-native business models to address systemic inefficiencies in healthcare, from specialty care management to enterprise AI deployment within health systems. FCV is investing at a moment when artificial intelligence is transitioning from an experimental tool to a foundational infrastructure layer in healthcare — and the firm’s expertise positions it to identify and back the most credible innovators in this space.
FCV Collective Welcomes Its Fifth Class
Alongside the Fund IV announcement, Frist Cressey Ventures is launching the fifth class of the FCV Collective — a curated group of 16 senior healthcare executives united by a shared commitment to durable, systems-level change. The Collective convenes throughout the year both virtually and in-person, facilitating peer learning, relationship-building, and engagement with policymakers in Washington, D.C. This policy connectivity gives FCV and its portfolio companies a meaningful edge in understanding the regulatory and legislative landscape shaping the future of healthcare.
What Fund IV Means for Healthcare Innovation
Founded by former U.S. Senate Majority Leader Bill Frist, MD, and Bryan Cressey, FCV has built a firm that combines elite political and policy access with deep clinical insight and investment discipline. Fund IV will serve as a catalyst for the next generation of healthcare companies improving millions of lives — through better outcomes, lower costs, and more equitable access to care.
